[1] Kaplan DE, Bosch J, Ripoll C, et al. AASLD practice guidance on risk stratification and management of portal hypertension and varices in cirrhosis[J]. Hepatology, 2023.
[2] Villanueva C, Albillos A, Geneca J, et al. β-blockers to prevent decompensation of cirrhosis in patients with clinically significant portal hypertension (PREDESCI): a randomised, double-blind, placebo-controlled, multicentre trial[J]. Lancet,2019,393(10181):1597-1608.
[3] Rowe IA, Villanueva C, Shearer JE,et al. Quantifying the benefit of non-selective betablockers in the prevention of hepatic decompensation: a Bayesian re-analysis of the PREDESCI trial[J]. Hepatology,2023, 78(2):530-539.
[4] Defranchis R, Bosch J, Garciatsao G, et al. Baveno VII - Renewing consensus in portal hypertension[J]. J Hepatol,2022,76(4):959-974.
[5] 冯丽娟,王宇,贾继东.肝硬化常见并发症的临床管理[J].肝脏, 2023,28(1):13-16.
[6] Xu T, Liu W, Huang R. Can albumin reduce the mortality of patients with cirrhosis and ascites? A meta-analysis of randomized controlled trials . Eur J Gastroenterol Hepatol, 2023, 35(1): 80-88.
[7] Bernardi M. Effective albumin - A novel paradigm in the management of decompensated liver cirrhosis[J]. J Transl Int Med,2023 ,11(1):11-14.
[8] Lee EW, Eghtesad B, Garcia-Tsao G, et al.AASLD Practice Guidance on the use of TIPS, variceal embolization, and retrograde transvenous obliteration in the management of variceal hemorrhage[J]. Hepatology,2024,79(1):224-250.
[9] Muhammad Farooq Hanif , Raja Omer Fiaz, et al. Comparison of carvedilol and propranolol for primary prophylaxis of esophageal variceal bleed in cirrhotic patients[J]. Pak J Pharm Sci,2023, 36(1):857-862.
[10] Larrue H, Damico G, Olivas P, Lv Y, et al. TIPS prevents further decompensation and improves survival in patients with cirrhosis and portal hypertension in an individual patient data meta-analysis[J]. J Hepatol,2023 ,79(3):692-703.
[11] Zacharias HD, Kamel F, Tan J, et al. Rifaximin for prevention and treatment of hepatic encephalopathy in people with cirrhosis[J]. Cochrane Database Syst Rev,2023,7(7):CD011585.
[12] Fagan A, Gavis EA, Gallagher ML, et al. A double-blind randomized placebo-controlled trial of albumin in outpatients with hepatic encephalopathy: HEAL study[J]. J Hepatol,2023, 78(2):312-321.
[13] Praharaj DL, Premkumar M, Roy A, et al.Norfloxacin for Spontaneous Bacterial Peritonitis Prophylaxis: A Randomized Controlled Trial[J]. J Clin Exp Hepatol,2022,12(2):336-342.
[14] Song S, Yang Y, Geng C. Norfloxacin versus alternative antibiotics for prophylaxis of spontaneous bacteria peritonitis in cirrhosis: a systematic review and meta-analysis[J]. BMC Infect Dis,2023,23(1):557.
[15] 中华医学会肝病学分会. 肝硬化腹水诊疗指南(2023年版)[J]. 中华肝脏病杂志,2023,31(8):813-826.
[16] Yang S, Zhang L, Jin Q, et al. Meld-sarcopenia score and skeletal muscle density predicts short-term readmission of patients with hepatic encephalopathy[J]. Eur J Radiol,2023,169(6):111-178.
[17] Thyloor Kenchappa S, Sharma S, Kumar M, et al. A Prospective Study of Prevalence and Impact of Sarcopenia on Short-term Mortality in Hospitalized Patients with Liver Cirrhosis[J]. J Clin Exp Hepatol,2023,13(11):946-954.
[18] Luo J, Yang D, Xu Z, et al. A prospective study on the differential association of sarcopenia and frailty with health outcomes in cirrhotic patients[J]. Dig Liver Dis,2023 ,55(11):1533-1542.
[19] Zhao J, Wu J, Li J, et al. Late evening snack and oral amino acid capsules improved respiratory quotient and Fischer ratio in patients with alcoholic liver cirrhosis[J]. Ann Hepatol,2023,28(4):100750.
[20] Aamann L, Dam G, Borre M, et al. Resistance Training Increases Muscle Strength and Muscle Size in Patients With Liver Cirrhosis[J]. Clin Gastroenterol Hepatol,2020,18(5):1179-1187.
[21] Kawaguchi T, Kawaguchi A, Hashida R, et al. Resistance exercise in combination with aerobic exercise reduces the incidence of serious events in patients with liver cirrhosis: a meta-analysis of randomized controlled trials[J]. Gastroenterology,2023.
[22] Liu J, Ma J, Yang C, et al. Sarcopenia in Patients with Cirrhosis after Transjugular Intrahepatic Portosystemic Shunt Placement[J] . Radiology, 2022,303(3): 711-719.
[23] Hey P, Chapman B, Wong D, et al. Transjugular intrahepatic portosystemic shunt insertion improves muscle mass but not muscle function or frailty measures[J]. Eur J Gastroenterol Hepatol,2023,35(9):997-1003.
[24] 国家心血管中心肺动脉高压专科联盟,国家心血管病专家委员会右心与肺血管病专业委员会.中国肺动脉高压诊治临床路径[J].中国循环杂志,2023,38(7):691-703.
[25] Humbert M, Kovacs G, Hoeper MM, et al. ESC/ERS Scientific Document Group. 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension[J]. Eur Respir J, 2023,61(1):2200879. |
